

**Table S1: Baseline and Follow Values for Phosphorus, Calcium, and Parathyroid Hormone For Ferric Citrate, Active Control, and Individual Subgroups of Active Control**

	Baseline Mean (Std) <sup>1</sup>					Week 52 Mean (Std) <sup>1</sup>				
	FC	AC	SC	CA	SC+CA	FC	AC	SC	CA	SC+CA
<b>Phosphorus (mg/dL)</b>	n=281,189	n=146,113	n=78,63	n=39,28	n=29,22	n=281,189	n=146,113	n=78,63	n=39,28	n=29,22
	7.39 (1.62)	7.54 (1.74)	7.46 (1.63)	7.35 (1.70)	7.99 (2.07)	5.36 (1.61)	5.38 (1.58)	5.36 (1.65)	5.32 (1.43)	5.53 (1.63)
<b>Calcium (mg/dL)</b>	n=281,189	n=146,113	n=78,63	n=39,28	n=29,22	n=281,189	n=146,113	n=78,63	n=39,28	n=29,22
	8.91 (0.78)	8.95 (0.85)	9.13 (0.70)	8.84 (0.83)	8.64 (1.11)	9.12 (0.86)	9.27 (0.92)	9.30 (0.81)	9.35 (1.06)	9.06 (1.01)
<b>Parathyroid Hormone (pg/dL)</b>	n=247,189	n=133,108	n=72,62	n=35,26	n=26,20	n=247,189	n=133,108	n=72,62	n=35,26	n=26,20
	606.0 (404.7)	602.0 (539.8)	627.1 (425.9)	418.9 (261.7)	783.7 (907.1)	453.4 (369.1)	431.5 (335.3)	504.7 (368.8)	299.9 (219.6)	406.3 (318.4)

FC, Ferric Citrate; AC, Active Control; SC, Sevelamer Carbonate; CA, Calcium Acetate; SC + CA, Combination of Sevelamer Carbonate and Calcium Acetate

<sup>1</sup>Analyses performed using last value carried forward imputation for missing measurements. Sample sizes indicate the number of patients with nonmissing baseline and follow-up data after the last value carried forward imputation, followed by the sample size for patients with nonmissing baseline and 12-month follow-up measurements.